glp 1 agonist new drug GLP-1 Receptor Agonists and Other Drugs The Power of Discovery: GLP-1

Diabetes Obes Metab 25(1):5667 Rosenstock J, Wysham C, Frias JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Take the medication in the morning on an empty stomach, 3060 minutes before eating

The most common adverse effects are mild gastrointestinal symptoms (nausea, vomiting, diarrhea) that typically occur at rates similar to placebo in controlled trials

Generally not recommended

Bolster nicotinamide adenine dinucleotide (NAD+) NAD+ is a coenzyme that lives in every cell of your body